Found and read this interesting article. If you can get past the scientific terminology it is a very interesting insight into the development and preclinical testing of SGN 75. Soundslike they followed in the footprints set by SGN 35. It also gives great insight into the potential value of SGEN ie. the linker system between the antibody and the cytotoxic payload. This article is not meant for Rick ! Only those interested in the science behind the investment.
Thank you. If I'm not mistaken this is their "new" linker and not the one currently used on SGN-35. It is not cleavable which may make it more efficient than the old technology. Does anyone have insight as to whether this will be used on all their new products or if it is target dependent? Also SGN-75 targets an antigen that is generally expressed on all or most carcinomas giving it widespread potential against many tumor types... frog